• Josh Disbrow

    Josh Disbrow

    Chairman & Chief Executive Officer

    Josh Disbrow has been in the life sciences industry for over twenty three years across pharmaceuticals, diagnostics, and medical devices. Prior to co-founding Aytu BioScience, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE) and co-founded and led the Luoxis Diagnostics subsidiary. Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company.

    Josh began as Arbor Pharmaceuticals’ second employee and oversaw the launch and subsequent growth of the company’s commercial operations. Josh led the commercial organization prior to the launch of the company’s first product, subsequently launching numerous products and scaling the team to over 150 people across sales, marketing, managed care, sales training, distribution, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of over $120 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular in vitro diagnostic company. Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices. Josh started his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh sits on the board of directors and is Chair of the Nominating and Governance Committee of Zynex, Inc. (NASDAQ: ZYXI), a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management from North Carolina State University and a Master of Business Administration from Wake Forest University.

  • Steven Boyd

    Steven Boyd


    Mr. Boyd is the Founder and Chief Investment Officer of Armistice Capital, a healthcare equity hedge fund he founded in 2012. Prior to founding Armistice, Mr. Boyd was a Research Analyst at Senator Investment Group, York Capital, and SAB Capital Management, where he focused on healthcare. Mr. Boyd began his career as an Analyst at McKinsey & Company.

    Mr. Boyd has served as a member of the board of directors of Cerecor (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare, since April 2017 and EyeGate Pharmaceuticals (NASDAQ: EYEG), a clinical-stage, specialty pharmaceutical company focused on disorders of the eye, since May 2018. Mr. Boyd received a B.S. in Economics and a B.A. in Political Science from The Wharton School of the University of Pennsylvania.

  • Gary Cantrell

    Gary Cantrell


    Gary Cantrell has thirty years’ experience in the life sciences industry ranging from clinical experience as a respiratory therapist to his current executive consulting business as Principal of Averaden, LLC. Prior to forming his professional consultancy, Gary served as CEO of Yasoo Health Inc., a global specialty nutritional company from 2007 to 2015, highlighted by the sale of its majority asset, AquADEKs, to Actavis in March 2015.

    He was also president of the Catevo Group, a North Carolina-based healthcare consulting firm, and Executive Vice President, Sales and Marketing at TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company. Mr. Cantrell started his pharmaceutical career at GSK, where he held multiple senior management positions in sales, marketing and business development over a period of 22 years. He has served as an advisor or board member of several emerging life science companies including his previous role as a board member at Flexible Stenting Solutions, Inc., which was sold to Cordis, while a division of Johnson & Johnson in March 2013. Mr. Cantrell is a graduate of Wichita State University.

  • Carl Dockery

    Carl Dockery

    Chair, Nominating & Governance Committee

    Carl Dockery is a financial executive with many years of experience in the insurance and reinsurance industry and more recently in 2006 as the founder of a registered investment advisory firm, Alpha Advisors, LLC. Carl’s 20-year career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as Vice President of Gulf Insurance Co. Ltd. of Grand Cayman.

    Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd’s and the London Underwriting Centre brokering various types of reinsurance placements. Carl was formerly a member of the Board of Directors of CytoDyn, Inc., a publicly traded biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and is an active investor in various healthcare companies through Alpha Ventures, the venture capital affiliate of Alpha Advisors. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities.

  • John Donofrio, Jr.

    John Donofrio, Jr.

    Chair, Audit Committee

    John Donofrio has over 25 years of experience in leading US and International teams in the pharmaceutical industry. John is a trusted finance leader with a proven track record of building strategy, financial management, leading teams, business partnering and strong collaboration among all levels of an organization.

    John has served as President of EPI Health since March of 2019. EPI Health is a growing specialty company based in Charleston, South Carolina with a focus on dermatology. Previously John served as Chief Financial Officer at TrialCard, a technology-enabled, pharmaceutical solutions company. Prior to joining TrialCard, John served as the Chief Financial Officer at Merz North America where he was responsible for overall strategy, management, reporting and controls of financial performance. He also lead the commercial analytics, data management, forecasting and operational excellence teams. Previous to Merz, John spent over 20 years at GSK in various U.S. and international roles of increasing responsibility and scope including commercial operations controlling, statutory accounting, manufacturing and supply, mergers and acquisition integration. John holds a bachelor’s degree in accounting from North Carolina State University and serves on the board of directors for Alliance Medical Ministries and Children’s Skin Disease Foundation.

  • Michael Macaluso

    Michael Macaluso

    Chair, Compensation Committee

    Michael Macaluso is the Chairman and Chief Executive Officer of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE). Mike founded Ampio Pharmaceuticals in 2010 through a merger with DMI Life Sciences, and he has been Chairman of the Board of Directors since the company’s inception.

    Mike was appointed Ampio’s Chief Executive Officer in January 2012 and has advanced the company’s preclinical development assets into late-stage clinical trials whereby Ampio is now engaged in the second US pivotal study with its lead therapeutic agent Ampion, a novel biologic being studied for the treatment of osteoarthritis of the knee. Prior to founding Ampio Mike was President, Chief Executive Officer, and a member of the Board of Directors of Isolagen, Inc. (AMEX: ILE), a biotechnology company.  From October 1998 until June 2001, Mike was the owner of Page International Communications, a global manufacturing business. Mike was also a founder and principal of International Printing and Publishing, a position Mike held from 1989 until 1997, when he sold that business to a private equity firm.  Mike is a graduate of Canisius College.

  • Ketan Mehta

    Ketan Mehta


    Mr. Mehta is the Founder, President, and Chief Executive Officer of Tris Pharma, a fully-integrated specialty pharmaceutical company focused on developing and commercializing advanced delivery technologies. Ketan founded Tris in 2,000 and has built the company into a leading specialty pharmaceutical company with over 500 employees.

    Tris develops, manufactures, licenses, and commercializes both branded and generic products directly and through commercial partnerships with both large and emerging pharmaceutical companies. Tris has developed many pharmaceutical technologies, including its extended-release platform LiquiXR® and holds over 150 patents in the U.S. and around the world. Before founding Tris Pharma, Ketan worked for Capsugel (formerly a division of Pfizer) in sales, marketing and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Ketan is a pharmacist by education and holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.